On November 18, GIANT BIOGENE fell 4.42% in Regular Trading, trading at HK$19.51, with turnover of HK$11.1664 million.
The move aligns with recent developments showing the company was removed from the MSCI China Index, with the change set to take effect after November 30, while Double 11 phase-one cosmetics GMV rose only 5% year over year, still above the broader market but slower than the 618 campaign.
Additional operating data cited by market reports indicated the company’s October growth turned negative, down 7.0% year over year versus 14.0% growth in September, mainly dragged by Comfy and Taobao/Tmall channels. Earlier interim results also showed first-half revenue of RMB2.918 billion, down 6.3%, and adjusted net profit of RMB946 million, down 21.5%, underscoring ongoing earnings pressure.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments